Joe Sandys

Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to $380 million, including an upfront payment of $270 million.

Cooley advised Bavarian Nordic, an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases, on its agreement to acquire the manufacturing and global rights to two commercial vaccines – Rabipur/RabAvert and Encepur – from GlaxoSmithKline, for €796 million. Partners Nicola Maguire and John Wilkinson led the Cooley team.